Jan Albert

Q: What Schools Are Affiliated With Jan Albert

Jan Albert is affiliated with the following schools: University of Dar es Salaam, University of Medicine, Taunggyi, KTH Royal Institute of Technology, Karolinska Institute

Jan Albert's AcademicInfluence.com Rankings

Jan Albert

Philosophy

#6991

World Rank

#10127

Historical Rank

Logic

#4069

World Rank

#5315

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Jan Albert's Degrees

Doctorate Medicine University of Medicine, Taunggyi
PhD Medical Science University of Medicine, Taunggyi

Why Is Jan Albert Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jan Albert's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) (2366)
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 (2020) (1479)
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults (2020) (1020)
Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype (1997) (665)
Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations (1989) (642)
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination (2020) (613)
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 (2021) (505)
Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates (1988) (465)
REPLICATIVE CAPACITY OF HUMAN IMMUNODEFICIENCY VIRUS FROM PATIENTS WITH VARYING SEVERITY OF HIV INFECTION (1986) (455)
Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. (1990) (424)
Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. (1999) (397)
Primary Human Immunodeficiency Virus Type 2 (HIV-2) Isolates, Like HIV-1 Isolates, Frequently Use CCR5 but Show Promiscuity in Coreceptor Usage (1999) (349)
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) (322)
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) (322)
Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR (2020) (312)
Regional brain and ventricular volumes in Tourette syndrome. (2001) (302)
Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. (1998) (300)
Accurate reconstruction of a known HIV-1 transmission history by phylogenetic tree analysis. (1996) (268)
Potential impact of seasonal forcing on a SARS-CoV-2 pandemic (2020) (267)
Transmission of drug-resistant HIV-1 is stabilizing in Europe. (2009) (259)
Simple, sensitive, and specific detection of human immunodeficiency virus type 1 in clinical specimens by polymerase chain reaction with nested primers (1990) (253)
Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants. (1998) (248)
Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys (1991) (204)
Population genomics of intrapatient HIV-1 evolution (2015) (190)
Majority of CD4+ T cells from peripheral blood of HIV-1–infected individuals contain only one HIV DNA molecule (2011) (187)
Updated European Recommendations for the Clinical Use of HIV Drug Resistance Testing (2004) (185)
The molecular clock of HIV-1 unveiled through analysis of a known transmission history. (1999) (184)
Comparison of variable region 3 sequences of human immunodeficiency virus type 1 from infected children with the RNA and DNA sequences of the virus populations of their mothers. (1993) (181)
Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. (1993) (179)
Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis (2015) (173)
ANTIBODY RESPONSE IN PRIMARY HUMAN IMMUNODEFICIENCY VIRUS INFECTION (1987) (173)
MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection (1994) (173)
Simplified strategy for detection of recombinant human immunodeficiency virus type 1 group M isolates by gag/env heteroduplex mobility assay. Study Group on Heterogeneity of HIV Epidemics in African Cities. (2000) (171)
Subtype‐specific problems with quantification of plasma HIV‐1 RNA (1997) (167)
Analysis of heterogeneous viral populations by direct DNA sequencing. (1993) (166)
Analysis of a rape case by direct sequencing of the human immunodeficiency virus type 1 pol and gag genes (1994) (166)
Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. (1999) (166)
Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. (1998) (164)
Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. (2000) (163)
Dual effect of interleukin 4 on HIV-1 expression: implications for viral phenotypic switch and disease progression. (1998) (160)
Replicative capacity, cytopathic effect and cell tropism of HIV (1989) (154)
Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. (2007) (151)
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe (2015) (147)
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach (2009) (141)
Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A-D. (1999) (137)
Few infected CD4+ T cells but a high proportion of replication-competent provirus copies in asymptomatic human immunodeficiency virus type 1 infection (1991) (137)
HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics (2013) (136)
Dynamics of HIV-1 Quasispecies during Antiviral Treatment Dissected Using Ultra-Deep Pyrosequencing (2010) (136)
Longitudinal Genetic Characterization Reveals That Cell Proliferation Maintains a Persistent HIV Type 1 DNA Pool During Effective HIV Therapy. (2015) (133)
Transmission of human immunodeficiency virus type 1 (HIV-1) from mother to child correlates with viral phenotype. (1993) (132)
Most HIV‐1 genetic subtypes have entered Sweden (1997) (129)
Biological and molecular characterization of subtype D, G, and A/D recombinant HIV-1 transmissions in Sweden. (1995) (127)
Characterization of Chlamydia trachomatis omp1 Genotypes among Sexually Transmitted Disease Patients in Sweden (2001) (125)
A new human retrovirus isolate of West African origin (SBL-6669) and its relationship to HTLV-IV, LAV-II, and HTLV-IIIB. (1987) (122)
Neopterin concentrations in cerebrospinal fluid and serum of individuals infected with HIV-1. (1989) (121)
Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates. (1996) (119)
Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates. (1998) (112)
Defining HIV-1 transmission clusters based on sequence data (2017) (110)
Dual tropism for macrophages and lymphocytes is a common feature of primary human immunodeficiency virus type 1 and 2 isolates (1994) (105)
Prevalence and Characteristics of Multinucleoside-Resistant Human Immunodeficiency Virus Type 1 among European Patients Receiving Combinations of Nucleoside Analogues (2000) (105)
Human immunodeficiency virus type 1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristics (1989) (105)
Establishment and stability of the latent HIV-1 DNA reservoir (2016) (103)
Isolation of human immunodeficiency virus (HIV) from plasma during primary HIV infection (1987) (101)
Characterization of subtype A HIV-1 from Africa by full genome sequencing. (1999) (101)
Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. (1993) (99)
Coevolution of RANTES Sensitivity and Mode of CCR5 Receptor Use by Human Immunodeficiency Virus Type 1 of the R5 Phenotype (2004) (98)
Viral Linkage in HIV-1 Seroconverters and Their Partners in an HIV-1 Prevention Clinical Trial (2011) (94)
Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections. (2010) (91)
Human immunodeficiency virus type 1 is present in the cerebrospinal fluid of a majority of infected individuals (1992) (88)
Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation. (2005) (87)
Molecular Epidemiology and MT-2 Cell Tropism of Russian HIV Type 1 Variants (1996) (83)
Timing and order of transmission events is not directly reflected in a pathogen phylogeny. (2014) (79)
In vivo mutation rates and the landscape of fitness costs of HIV-1 (2017) (78)
Towards an understanding of the migration of Crimean-Congo hemorrhagic fever virus. (2010) (77)
Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. (2005) (76)
Pyrosequencing for Detection of Lamivudine-Resistant Hepatitis B Virus (2004) (76)
Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease. (1991) (75)
The biological phenotype of HIV-1 is usually retained during and after sexual transmission. (1994) (75)
New human and simian HIV-related retroviruses possess functional transactivator (tat) gene (1987) (74)
PCR-Induced Transitions Are the Major Source of Error in Cleaned Ultra-Deep Pyrosequencing Data (2013) (73)
Outbreak of enterovirus D68 of the new B3 lineage in Stockholm, Sweden, August to September 2016 (2016) (73)
Low Prevalence of Transmitted Drug Resistance in Patients Newly Diagnosed with HIV-1 Infection in Sweden 2003–2010 (2012) (72)
HIV ANTIGENAEMIA AND VIRUS ISOLATION FROM PLASMA DURING PRIMARY HIV INFECTION (1987) (72)
Infection of cynomolgus monkeys with HIV-2 protects against pathogenic consequences of a subsequent simian immunodeficiency virus infection. (1990) (69)
A real-time TaqMan PCR for routine quantitation of cytomegalovirus DNA in crude leukocyte lysates from stem cell transplant patients. (2003) (69)
Expert consensus statement on the science of HIV in the context of criminal law (2018) (68)
Molecular characterization of human immunodeficiency virus (HIV)-1 and -2 in individuals from guinea-bissau with single or dual infections: predominance of a distinct HIV-1 subtype A/G recombinant in West Africa. (1999) (68)
Molecular and biological characterization of a replication competent human immunodeficiency type 2 (HIV-2) proviral clone. (1989) (68)
Long–term protection against SIV–induced disease in macaques vaccinated with a live attenuated HIV–2 vaccine (1995) (68)
Functional monocytic myeloid-derived suppressor cells increase in blood but not airways and predict COVID-19 severity. (2021) (67)
Experimental infection of cynomolgus monkeys (Macaca fascicularis) with HIV-2. (1989) (67)
Isolation frequency of human immunodeficiency virus from cerebrospinal fluid and blood of patients with varying severity of HIV infection. (1988) (66)
Fatal encephalitis associated with coronavirus OC43 in an immunocompromised child (2020) (66)
Treatment history and baseline viral load, but not viral tropism or CCR‐5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment (1998) (65)
MT-2 cell tropism of human immunodeficiency virus type 1 isolates as a marker for response to treatment and development of drug resistance. (1994) (64)
Sampling bias and incorrect rooting make phylogenetic network tracing of SARS-COV-2 infections unreliable (2020) (63)
Neutralizing antibodies and viral characteristics in mother‐to‐child transmission of HIV‐1 (1993) (63)
HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use (2003) (63)
Vaccine protection against HIV-2 infection in cynomolgus monkeys. (1991) (63)
Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera (1992) (62)
Global Dispersal Pattern of HIV Type 1 Subtype CRF01_AE: A Genetic Trace of Human Mobility Related to Heterosexual Sexual Activities Centralized in Southeast Asia. (2015) (60)
Cerebrospinal fluid mononuclear cell counts influence CSF HIV-1 RNA levels. (1998) (60)
Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. (2008) (59)
Monitoring Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors by Pyrosequencing (2001) (57)
Inhibition of Early and Late Events of the HIV-1 Replication Cycle by Cytoplasmic Fab Intrabodies against the Matrix Protein, p17 (1997) (57)
Tempo and Mode of Nucleotide Substitution in gag andenv Gene Fragments in Human Immunodeficiency Virus Type 1 Populations with a Known Transmission History (1998) (57)
Coexistence of subtypes B, F, and as B/F env recombinant of HIV type 1 in Buenos Aires Argentina. (1996) (57)
Correction: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis (2015) (57)
HIV-1 transmission between MSM and heterosexuals, and increasing proportions of circulating recombinant forms in the Nordic Countries (2016) (56)
Easy and accurate reconstruction of whole HIV genomes from short-read sequence data with shiver (2018) (55)
Coreceptor usage and RANTES sensitivity of non-syncytium-inducing HIV-1 isolates obtained from patients with AIDS. (1999) (54)
Coreceptor change appears after immune deficiency is established in children infected with different HIV-1 subtypes. (2002) (52)
Molecular Epidemiology of Neisseria gonorrhoeae: Sequence Analysis of the porB Gene Confirms Presence of Two Circulating Strains (2002) (52)
ISOLATION OF HUMAN IMMUNODEFICIENCY VIRUS FROM CEREBROSPINAL FLUID OF ANTIBODY-POSITIVE VIRUS CARRIER WITHOUT NEUROLOGICAL SYMPTOMS (1986) (50)
The global spread of HIV-1 subtype B epidemic (2016) (50)
pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy. (2003) (50)
The Trophoblastic Epithelial Barrier Is Not Infected in Full-Term Placentae of Human Immunodeficiency Virus-Seropositive Mothers Undergoing Antiretroviral Therapy (1999) (49)
Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe (2017) (49)
Quality Control Assessment of Human Immunodeficiency Virus Type 2 (HIV-2) Viral Load Quantification Assays: Results from an International Collaboration on HIV-2 Infection in 2006 (2008) (49)
Identification of two CRF11-cpx genomes and two preliminary representatives of a new circulating recombinant form (CRF13-cpx) of HIV type 1 in Cameroon. (2002) (49)
Human immunodeficiency virus infection of the brain I. Virus isolation and detection of HIV specific antibodies in the cerebrospinal fluid of patients with varying clinical conditions (1988) (49)
Length variation of glycoprotein 120 V2 region in relation to biological phenotypes and coreceptor usage of primary HIV type 1 isolates. (2001) (49)
COVID-19 Scenarios: an interactive tool to explore the spread and associated morbidity and mortality of SARS-CoV-2 (2020) (47)
A capture enzyme immunoassay for detection of HIV-2/SIV antigen. (1991) (47)
Temporal Trends in the Swedish HIV-1 Epidemic: Increase in Non-B Subtypes and Recombinant Forms over Three Decades (2014) (47)
Human immunodeficiency virus type 1 and cytomegalovirus in saliva (1993) (46)
Replicative capacity of HIV-2, like HIV-1, correlates with severity of immunodeficiency. (1990) (46)
Analysis of the V3 loop in neutralization-resistant human immunodeficiency virus type 1 variants by direct solid-phase DNA sequencing. (1991) (46)
Performance of Ultra-Deep Pyrosequencing in Analysis of HIV-1 pol Gene Variation (2011) (46)
Dynamics of Two Separate but Linked HIV-1 CRF01_AE Outbreaks among Injection Drug Users in Stockholm, Sweden, and Helsinki, Finland (2010) (46)
Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe (2014) (44)
Biological characterization of paired human immunodeficiency virus type 1 isolates from blood and cerebrospinal fluid. (1989) (44)
Limited cross-border infections in patients newly diagnosed with HIV in Europe (2013) (44)
Evasion of neutralising antibodies by omicron sublineage BA.2.75 (2022) (43)
The role of the humoral immune response in HIV infection (1996) (43)
Patterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group (2014) (43)
HIV-2 genetic variation and DNA load in asymptomatic carriers and AIDS cases in Guinea-Bissau. (1997) (42)
Yet another subtype of HIV type 1? (1995) (42)
Comparison of Serologic and Genetic porB-Based Typing of Neisseria gonorrhoeae: Consequences for Future Characterization (2003) (42)
Site‐directed ELISA with synthetic peptides representing the HIV transmembrane glycoprotein (1987) (42)
Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations. (1994) (41)
Experimental infection of cynomolgus monkeys (Macaca fascicularis) with simian immunodeficiency virus (SIVsm). (1989) (41)
Link between the X4 phenotype in human immunodeficiency virus type 1-infected mothers and their children, despite the early presence of R5 in the child. (2002) (41)
Dynamic changes in HIV‐1 quasispecies from azidothymidine (AZT)‐treated patients (1992) (41)
Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study (2022) (40)
Correlation between HIV sequence evolution, specific immune response and clinical outcome in vertically infected infants (1997) (40)
Biological phenotype of HIV type 2 isolates correlates with V3 genotype. (1996) (40)
Error rates, PCR recombination, and sampling depth in HIV-1 whole genome deep sequencing. (2017) (39)
A simple and sensitive 'in-house' method for determining genotypic drug resistance in HIV-1. (2003) (39)
Evaluation of a prototype Amplicor PCR assay for detection of human immunodeficiency virus type 1 DNA in blood samples from Tanzanian adults infected with HIV-1 subtypes A, C and D. (2000) (38)
Estimating time of HIV-1 infection from next-generation sequence diversity (2017) (38)
A new cell line-based neutralization assay for primary HIV type 1 isolates. (2002) (38)
Coreceptor Usage of HIV‐1 Isolates Representing Different Genetic Subtypes Obtained From Pregnant Cameroonian Women (2000) (38)
Molecular epidemiology and MT-2 cell tropism of Russian HIV type 1 variant. (1996) (38)
Increased Sensitivity to Broadly Neutralizing Antibodies of End-Stage Disease R5 HIV-1 Correlates with Evolution in Env Glycosylation and Charge (2011) (38)
Ugandan HIV-1 V3 loop sequences closely related to the U.S./European consensus. (1992) (37)
Frequent Respiratory Viral Infections in Children with Febrile Neutropenia - A Prospective Follow-Up Study (2016) (37)
Prevalence of drug resistance and importance of viral load measurements in Honduran HIV‐infected patients failing antiretroviral treatment (2010) (37)
Prevalence and risk factors for HTLV-II infection in 913 injecting drug users in Stockholm, 1994. (1997) (35)
CD8+ T cells from HIV type 1-seronegative individuals suppress virus replication in acutely infected cells. (1997) (35)
Radioimmunoprecipitation and Western blotting with sera of human immunodeficiency virus infected patients: a comparative study. (1987) (35)
Epidemiology of HIV in Estonia. (2001) (35)
Trends and Predictors of Transmitted Drug Resistance (TDR) and Clusters with TDR in a Local Belgian HIV-1 Epidemic (2014) (35)
Simplified Strategy for Detection of Recombinant Human Immunodeficiency Virus Type 1 Group M Isolates bygag/env Heteroduplex Mobility Assay (2000) (35)
Assay of plasma samples representing different HIV-1 genetic subtypes: an evaluation of new versions of the amplicor HIV-1 monitor assay. (1999) (35)
Virtually full-length sequences of HIV type 1 subtype J reference strains. (1999) (35)
Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants (2021) (35)
Improved Detection of HIV‐2 DNA in Clinical Samples Using a Nested Primer‐Based Polymerase Chain Reaction (1992) (35)
Immunological and virological interactions in patients receiving passive immunotherapy with HIV-1 neutralizing monoclonal antibodies. (1994) (33)
An HIV type 1 subtype A outbreak among injecting drug users in Latvia. (1999) (33)
Naturally occurring HIV-1 isolates with differences in replicative capacity are distinguished by in situ hybridization of infected cells. (1990) (33)
Studies on toll-like receptor stimuli responsiveness in HIV-1 and HIV-2 infections. (2009) (32)
HIV-2 Genetic Evolution in Patients with Advanced Disease Is Faster than That in Matched HIV-1 Patients (2010) (31)
Risk of HIV transmission from patients on antiretroviral therapy: A position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy (2014) (31)
Rapid Viral Decay in Simian Immunodeficiency Virus-Infected Macaques Receiving Quadruple Antiretroviral Therapy (2006) (31)
HIV-1 Transmission Cluster with M41L ‘Singleton’ Mutation and Decreased Transmission of Resistance in Newly Diagnosed Swedish Homosexual Men (2006) (31)
Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies (2022) (31)
Antiretroviral treatment of HIV infection: Swedish recommendations 2007 (2007) (31)
Science in court: the myth of HIV fingerprinting. (2011) (30)
Challenges with Using Primer IDs to Improve Accuracy of Next Generation Sequencing (2015) (30)
Apparent selection against transmission of zidovudine-resistant human immunodeficiency virus type 1 variants. (1994) (30)
Evolution of DC-SIGN use revealed by fitness studies of R5 HIV-1 variants emerging during AIDS progression (2008) (30)
Transmitted drug resistance and type of infection in newly diagnosed HIV-1 individuals in Honduras. (2010) (30)
Molecular epidemiology and the evolution of human coxsackievirus A6. (2016) (29)
Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs. (2013) (29)
MT‐2 tropism and CCR‐5 genotype strongly influence disease progression in HIV‐1‐infected individuals (1998) (28)
Forensic evidence by DNA sequencing (1993) (27)
Evidence of the existence of a new circulating recombinant form of HIV type 1 subtype A/J in Cameroon. The European Network on the Study of In Utero Transmission of HIV-1. (2000) (27)
Seropositivity in blood donors and pregnant women during the first year of SARS‐CoV‐2 transmission in Stockholm, Sweden (2021) (27)
Impaired parathyroid hormone release in human immunodeficiency virus infection. (1994) (26)
Interplay of HIV-1 phenotype and neutralizing antibody response in pathogenesis of AIDS. (1996) (25)
Comparison of in-house and commercial sample preparation and PCR amplification systems for detection of human immunodeficiency virus type 1 DNA in blood samples from Tanzanian adults (1997) (25)
HIV-1 infection of normal human macrophage cultures: implication for silent infection. (1990) (25)
Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients (2012) (25)
Differential Pathogenesis of Primary CCR5-Using Human Immunodeficiency Virus Type 1 Isolates in Ex Vivo Human Lymphoid Tissue (2005) (25)
A formalin inactivated whole SIVmac vaccine in Ribi adjuvant protects against homologous and heterologous SIV challenge. (1992) (25)
Population genomics of intrapatient HIV-1 (2015) (25)
Antiretroviral treatment for HIV infection: Swedish recommendations 2016 (2017) (25)
Trends in Antiretroviral Therapy and Prevalence of HIV Drug Resistance Mutations in Sweden 1997–2011 (2013) (24)
Towards Estimation of HIV-1 Date of Infection: A Time-Continuous IgG-Model Shows That Seroconversion Does Not Occur at the Midpoint between Negative and Positive Tests (2013) (24)
Brain-derived cells can be infected with HIV isolates derived from both blood and brain. (1991) (23)
CCR5 or CXCR4 is required for efficient infection of peripheral blood mononuclear cells by promiscuous human immunodeficiency virus type 2 primary isolates. (2002) (23)
Improved tissue culture technique for production of poorly replicating human immunodeficiency virus strains. (1988) (23)
A highly virulent variant of HIV-1 circulating in the Netherlands (2022) (23)
Can the further clinical development of bevirimat be justified? (2010) (22)
How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts’ Opinion and Its Influence on the Projected Public Health Impact (2016) (22)
Inference of Transmission Network Structure from HIV Phylogenetic Trees (2016) (22)
Acid hydrolysis of serum samples to increase detection of HIV antigen. (1988) (22)
Multiple HIV-1 introductions into the Swedish intravenous drug user population. (2008) (21)
High intrapatient HIV-1 evolutionary rate is associated with CCR5-to-CXCR4 coreceptor switch. (2013) (21)
The influence of MT‐2 tropism on the prognostic implications of the Δ32 deletion in the CCR‐5 gene (1997) (21)
Coreceptor usage of HIV-1 isolates representing different genetic subtypes obtained from pregnant Cameroonian women. European Network for In Utero Transmission of HIV-1. (2000) (21)
Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron) (2021) (20)
Treatment of HIV infection: Swedish recommendations 2009 (2009) (20)
High plasma levels of soluble fas in HIV type 1-infected subjects are not normalized during highly active antiretroviral therapy. (2000) (20)
REPLICATIVE AND CYTOPATHIC CHARACTERISTICS OF HIV-2 AND SEVERITY OF INFECTION (1989) (20)
Airway antibodies emerge according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccination (2020) (19)
Antigen detection is a reliable method for evaluating HIV/SIV neutralization assays. (1993) (19)
IgG subclass responses to a transmembrane protein (gp41) peptide in HIV infection. (1989) (19)
HIV‐1 evolution in relation to molecular epidemiology and antiretroviral resistance (2011) (19)
Report of a consensus workshop, Siena, Italy, January 17-18, 1992. Early diagnosis of HIV infection in infants. (1992) (19)
Coexistence of two clades of enterovirus D68 in pediatric Swedish patients in the summer and fall of 2014 (2015) (18)
Analysis of a subclass-restricted HIV-1 gp41 epitope by omission peptides. (1989) (18)
Transmission of the X4 phenotype of HIV-1: is there evidence against the "random transmission" hypothesis? (2012) (18)
Structural basis of Omicron neutralization by affinity-matured public antibodies (2022) (18)
A Single-Stranded Oligonucleotide Inhibits Toll-Like Receptor 3 Activation and Reduces Influenza A (H1N1) Infection (2019) (18)
Phylogenetic analysis of the Latvian HIV-1 epidemic. (2012) (18)
Loss of synergistic response to combinations containing AZT in AZT-resistant HIV-1. (1992) (18)
Intra- and interpatient evolution of enterovirus D68 analyzed by whole-genome deep sequencing (2018) (17)
Characterization of novel recombinant HIV-1 genomes using the branching index. (2003) (17)
Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish Recommendations 2007 (2008) (17)
Two cases of oral-to-genital HIV-1 transmission (1997) (17)
Delayed HIV diagnosis common in Sweden, 2003–2010 (2014) (17)
Quantification of HIV-1 using multiple quantitative polymerase chain reaction standards and bioluminometric detection. (2001) (17)
A Single Early Introduction of HIV-1 Subtype B into Central America Accounts for Most Current Cases (2013) (16)
Padlock Probe Assay for Detection and Subtyping of Seasonal Influenza. (2018) (16)
Quantification of HIV-1 using multiple competitors in a single-tube assay. (1996) (16)
Autologous neutralizing antibodies to SIVsm in cynomolgus monkeys correlate to prognosis. (1993) (16)
Association between serum neopterin concentrations and in vitro replicative capacity of HIV-1 isolates. (1989) (15)
Low prevalence of transmitted drug resistance among newly diagnosed HIV‐1 patients in Latvia (2010) (15)
Re-emergence of enterovirus D68 in Europe after easing the COVID-19 lockdown, September 2021 (2021) (15)
Cross-Reactive T-Helper Responses in Patients Infected with Different Subtypes of Human Immunodeficiency Virus Type 1 (2000) (15)
Interactions between seasonal human coronaviruses and implications for the SARS-CoV-2 pandemic: A retrospective study in Stockholm, Sweden, 2009-2020 (2020) (14)
Biological phenotypes of HIV-1 in pathogenesis and transmission. (1994) (13)
Cross-Resistance between AZT, ddl and other Antiretroviral Drugs in Primary Isolates of HIV-1 (1994) (13)
SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses (2022) (13)
Biological phenotype of HIV-1 and transmission. (1995) (12)
Antiretroviral treatment for HIV infection: Swedish recommendations 2019 (2020) (12)
Prevalence of transmitted HIV‐1 drug resistance among female sex workers and men who have sex with men in El Salvador, Central America (2012) (12)
Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish Recommendations 2010 (2011) (12)
HIV isolation and antigen detection in infected individuals and their seronegative sexual partners. (1988) (12)
A Method to Estimate the Size and Characteristics of HIV-positive Populations Using an Individual-based Stochastic Simulation Model (2015) (11)
Transmission of drug-resistance in Europe is characterized by single mutations and revertants (2006) (11)
Short communication: high prevalence of drug resistance in HIV type 1-infected children born in Honduras and Belize 2001 to 2004. (2011) (11)
Development and Evaluation of an Oligonucleotide Ligation Assay for Detection of Drug Resistance-Associated Mutations in the Human Immunodeficiency Virus Type 2 pol Gene (2007) (11)
Evaluation of Bio-Rad Geenius HIV-1 and -2 Assay as a Confirmatory Assay for Detection of HIV-1 and -2 Antibodies (2014) (11)
Stable biological and antigenic characteristics of HIV-2SBL6669 in nonpathogenic infection of macaques. (1994) (11)
A Phylogenetic Analysis of Human Immunodeficiency Virus Type 1 Sequences in Kiev: Findings Among Key Populations (2017) (11)
Peptide serology for analysis of the inter- and intra‐individual variation in the HIV‐1 V3 domain (1994) (11)
Blood-derived macrophages produce IL-1, but not TNF-alpha, after infection with HIV-1 isolates from patients at different stages of disease. (1992) (11)
Easy and Accurate Reconstruction of Whole HIV Genomes from Short-Read Sequence Data (2016) (10)
Impaired B cells survival upon production of inflammatory cytokines by HIV-1 exposed follicular dendritic cells (2016) (10)
Comparison of HIV-1 resistance profiles in plasma RNA versus PBMC DNA in heavily treated patients in Honduras, a resource-limited country. (2012) (10)
Therapy Failure Resulting from Superinfection by a Drug-Resistant HIV Variant (2012) (10)
Monoclonal antibodies to native HIV type 1 reverse transcriptase and their interaction with enzymes from different subtypes. (2000) (10)
Getting more from heterogeneous HIV-1 surveillance data in a high immigration country: estimation of incidence and undiagnosed population size using multiple biomarkers (2018) (10)
Seropositivity in blood donors and pregnant women during 9-months of SARS-CoV-2 transmission in Stockholm, Sweden (2020) (10)
Performance of the Simplexa™ Flu A/B & RSV Direct Kit on respiratory samples collected in saline solution (2014) (9)
Prophylaxis and treatment of HIV-1 infection in pregnancy – Swedish Recommendations 2017 (2018) (9)
Trends of HIV-1 incidence with credible intervals in Sweden 2002-09 reconstructed using a dynamic model of within-patient IgG growth. (2015) (9)
Molecular Epidemiology and Evolutionary Trajectory of Emerging Echovirus 30, Europe (2021) (9)
Increase in transmitted drug resistance in migrants from sub-Saharan Africa diagnosed with HIV-1 in Sweden (2018) (9)
Implications of HIV Drug Resistance on First- and Second-Line Therapies in Resource-Limited Settings: Report from a Workshop Organized by the Collaborative HIV and Anti-HIV Drug Resistance Network (2013) (9)
Functional myeloid-derived suppressor cells expand in blood but not airways of COVID-19 patients and predict disease severity (2020) (9)
Six-week follow-up after HIV-1 exposure: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy (2016) (8)
SIV infection of monkey spleen cells including follicular dendritic cells in different stages of disease. (1996) (8)
Use of Multiple Competitors for Quantification of Human Immunodeficiency Virus Type 1 RNA in Plasma (1998) (8)
HIV-1-specific antibodies in cerebrospinal fluid mediate cellular cytotoxicity and neutralization. (1989) (8)
Antiretroviral treatment of HIV infection: Swedish recommendations 2005 (2006) (8)
Estimates of HIV transmitted drug resistance can be inflated due to natural sequence polymorphisms. (2011) (8)
Antigenic Variation within the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120: Effects on Chemokine Receptor Utilization (2001) (8)
Four SARS-CoV-2 Genome Sequences from Late April in Stockholm, Sweden, Reveal a Rare Mutation in the Spike Protein (2020) (7)
In-vivo mutation rates and fitness landscape of HIV-1 (2016) (7)
Children and young people with perinatal HIV in Europe: epidemiological situation in 2014 and implications for the future (2016) (7)
Effect of resistance on combination chemotherapy for human immunodeficiency virus infection. (1993) (7)
Cerebrospinal fluid viral load, virus isolation, and intrathecal immunoactivation in HIV type 2 infection. (2004) (7)
Error rates, PCR recombination, and sampling depth in HIV-1 Whole Genome Deep Sequencing (2016) (7)
Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2013 (2014) (6)
52 An in vitro model for determination of the rate of resistance development in HIV (1993) (6)
Daily Sampling of an HIV-1 Patient with Slowly Progressing Disease Displays Persistence of Multiple env Subpopulations Consistent with Neutrality (2011) (6)
Contagiousness in treated HIV-1 infection (2020) (6)
Simple, Sensitive, andSpecific Detection ofHuman Immunodeficiency VirusType1inClinical Specimens by Polymerase ChainReaction withNestedPrimers (1990) (6)
Evolution, geographic spreading, and demographic distribution of Enterovirus D68 (2020) (6)
Serum levels and catabolism of 3'-azido-3'-deoxythymidine in vivo measured using a specific radioimmunoassay. (1990) (6)
Inferring transmission heterogeneity using virus genealogies: Estimation and targeted prevention (2020) (5)
FewInfected CD4+T Cells buta HighProportion ofReplication- Competent Provirus Copies inAsymptomatic Human Immunodeficiency VirusType1 Infection (1991) (5)
Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. (1989) (5)
Impact of seasonal forcing on a potential SARS-CoV-2 pandemic (2020) (5)
Longitudinal ultradeep characterization of HIV type 1 R5 and X4 subpopulations in patients followed from primary infection to coreceptor switch. (2013) (5)
Analysis of the HIV‐1 Envelope V3‐Loop Sequences from Ten Mother‐Child Pairs (1993) (4)
Antiretroviral therapy does not induce HIV type 1-specific neutralizing activity against autologous HIV type 1 isolates. (2006) (4)
A New Genetic Subtype of HIV-1 (1996) (4)
Airway antibodies wane rapidly after COVID-19 but B cell memory is generated across disease severity (2020) (4)
Challenges in modelling the proportion of undiagnosed HIV infections in Sweden (2019) (4)
Long-term immunotherapy in HIV infection, combined with short-term antiretroviral treatment (1999) (4)
A systematic approach that identifies 11 new mutations as indicators of transmission of resistance (2003) (4)
Differential transmission of HIV-1 and HIV-2 (1997) (3)
Probabilistic classification of anti‐SARS‐CoV‐2 antibody responses improves seroprevalence estimates (2022) (3)
Molecular epidemiology and the evolution of human coxsackievirus A 6 (2016) (3)
Early development of anti-HIV IgG (1990) (3)
Antibody phenotypes and probabilistic seroprevalence estimates during the emergence 1 of SARS-CoV-2 in Sweden 2 (2020) (3)
Disease-associated antibody phenotypes and probabilistic seroprevalence estimates during the emergence of SARS-CoV-2 (2020) (3)
Probabilistic approaches for classifying highly variable anti-SARS-CoV-2 antibody responses (2020) (3)
Corrigendum to “A simple and sensitive ‘in-house’ method for determining genotypic drug resistance in HIV-1” (2003) (2)
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine – An Interim Analysis (2022) (2)
Antibody responses to SARS-CoV-2 train machine learning to assign likelihood of past infection during virus emergence in Sweden (2020) (2)
Author response: Population genomics of intrapatient HIV-1 evolution (2015) (2)
Diagnosis of Human Immunodeficiency Virus Infection by Polymerase Chain Reaction (1992) (2)
Multiple Competitors for Single-Tube Quantification of HIV-1 DNA (1997) (2)
Correction: Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe (2017) (2)
Delayed generation of functional virus-specific circulating T follicular helper cells correlates with severe COVID-19 (2022) (2)
Short communication: HIV type 2 dynamics. (2005) (2)
Limited cross-border infections in patients newly diagnosed with HIV in Europe (2013) (1)
Human influenza virus infection elicits distinct patterns of monocyte and dendritic cell mobilization in blood and the nasopharynx (2022) (1)
Comprehensive analysis of intra- and interpatient evolution of enterovirus D68 by whole-genome deep sequencing (2018) (1)
HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics (2013) (1)
High-throughput sequencing reveals a high prevalence of pretreatment HIV-1 drug resistance in Sweden. (2020) (1)
HIV-1 / 2 as a confirmatory assay for 1 detection of HIV-1 / 2 antibodies 2 (2014) (1)
Coreceptor usage of primary HIV type 1 isolates obtained from different lymph node subsets. (2005) (1)
Combining biomarker and virus phylogenetic models improves HIV-1 epidemiological source identification (2021) (1)
SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein (2020) (1)
Replication in Human Intestinal Enteroids of Infectious Norovirus from Vomit Samples (2021) (1)
Towards a world free from HIV and AIDS? (2011) (1)
Correlation between estimated fitness under protease and reverse transcriptase inhibitor selective pressure and viral load or CD4 count in recently diagnosed treatment-naïve patients (2008) (0)
Immunodominant antigenic sites in primate immunodeficiency viruses and in vivo protection. (1991) (0)
Increased sensitivity to neutralizing antibodies of end-stage disease R5 HIV-1 is concomitant with reduced gp120 glycosylation and increased plus charge (2010) (0)
Biological Variability of HIV-1 (2000) (0)
Impaired B cells survival upon production of inflammatory cytokines by HIV-1 exposed follicular dendritic cells (2016) (0)
A35 Viral evolution and innate immune responses during acute HIV-1 infection and their association with disease pathogenesis (2017) (0)
[Darwin's principles direct the development of A/H1N1. Influenza virus evolution enormously complex--the new influenza is not and exception]. (2009) (0)
Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients (2012) (0)
Development and evaluation of the oligonucleotide ligation assay (OLA) for the detection of drug resistance mutations in HIV-2 patients on antiretroviral therapy (2006) (0)
Introduction: HIV neutralizing antibodies: relevance to pathogenesis and vaccines (2007) (0)
Erratum: Tempo and mode of nucleotide substitution in gag and env gene fragments in human immunodeficiency virus type 1 populations with a known transmission history (Journal of Virology 71:6 (4761-4770)) (1998) (0)
HIV neutralizing antibodies: relevance to pathogenesis and vaccines (2007) (0)
Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance (2015) (0)
Genetic diversity of HIV-1 in Europe and its demographic determinants (2002-2005) (2011) (0)
A5 Near full-length HIV-1 genome sequencing in newly diagnosed individuals in Sweden (2019) (0)
[Human immunodeficiency virus (HIV)--an explosion of knowledge in the field of virology]. (1989) (0)
Do circulating HIV vaccine plasmids contribute to immunogenicity in humans? (2006) (0)
Inferring the multiplicity of founder variants initiating HIV-1 infection: a systematic review and individual patient data meta-analysis. (2021) (0)
Phylogenetic estimation of the viral fitness landscape of HIV-1 set-point viral load (2022) (0)
[Precision diagnostics in clinical microbiology]. (2021) (0)
Original Article Comparison of HIV-1 resistance profiles in plasma RNA versus PBMC DNA in heavily treated patients in Hondu- ras, a resource-limited country (2012) (0)
Persistence ofAzidothymidine-Resistant Human Immunodeficiency VirusType1RNA Genotypes inPosttreatment Sera (1992) (0)
TREATMENT-ASSOCIATED POLYMORPHISMS IN PROTEASE BUT NOT IN REVERSE TRANSCRIPTASE ARE SIGNIFICANTLY ASSOCIATED WITH HIGHER VIREMIA AND LOWER CD4 CELL COUNT IN RECENTLY DIAGNOSED TREATMENT-NAIVE PATIENTS (2010) (0)
reaction with nested primers. clinical specimens by polymerase chain human immunodeficiency virus type 1 in Simple, sensitive, and specific detection of (2013) (0)
Different Pathogenesis of CCR5-Using Primary HIV-1 Isolates from Non-Switch and Switch Virus Patients in Human Lymphoid Tissue Ex Vivo (2005) (0)
The Blocking Of Slow/low Type Hiv Replication In Cd4+ Cell Lines Takes Place After Provirus Formation (1993) (0)
HIV-1gp4lepitope byomission peptides (1989) (0)
Functional SARS-CoV-2 cross-reactive CD4+ T cells established in early childhood decline with age (2023) (0)
HumanImmunodeficiency VirusType1IsPresent inthe Cerebrospinal Fluid ofa Majority ofInfected Individuals (1992) (0)
Reply to Redd et al (2011) (0)
[The human immunodeficiency virus (HIV)--an explosion of knowledge in virology]. (1988) (0)
Simpliﬁed Strategy for Detection of Recombinant Human Immunodeﬁciency Virus Type 1 Group M Isolates by gag/env Heteroduplex Mobility Assay OF HIV EPIDEMICS IN AFRICAN (1999) (0)
Development and evaluation of new therapeutic interventions for chronic hepatitis C virus infection (2015) (0)
HIV-1 infection of normal human macrophage cultures: implication for silent infection. (1990) (0)
HIV-1 Infection in Cyprus, the Eastern Mediterranean European Frontier: A Densely Sampled Transmission Dynamics Analysis from 1986 to 2012 (2018) (0)

This paper list is powered by the following services:

Other Resources About Jan Albert

ki.se

What Schools Are Affiliated With Jan Albert?

Jan Albert is affiliated with the following schools:

Jan Albert's Academic­Influence.com Rankings